Esophageal impedance baselines in infants before and after placebo and proton pump inhibitor therapy

Neurogastroenterology and Motility

Volumn 24, Issue 8, 2012, Pages

  Loots, C M ^a   Wijnakker, R ^b   van Wijk, M P ^a   Davidson, G ^b,c   Benninga, M A ^a   Omari, T I ^b,c  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Diagnostic testing; Esophageal motility; Esophagus; Pediatrics; PH impedance monitoring; Proton pump inhibitors

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE; PLACEBO;

ARTICLE; CLINICAL ARTICLE; CRYING; ESOPHAGUS; ESOPHAGUS MUCOSA; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; IMPEDANCE; INFANT; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYMPTOM; TREATMENT RESPONSE; VOMITING;

DOUBLE-BLIND METHOD; ELECTRIC IMPEDANCE; ESOPHAGEAL PH MONITORING; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84863816178     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2012.01922.x     Document Type: Article

References (28)

1. Loots CM, Benninga MA, Davidson GP et al. Addition of pH-impedance monitoring to standard pH monitoring increases the yield of symptom association analysis in infants and children with gastroesophageal reflux. J Pediatr 2009; 154: 248-52.
2. Rosen R, Lord C, Nurko S. The sensitivity of multichannel intraluminal impedance and the pH probe in the evaluation of gastroesophageal reflux in children. Clin Gastroenterol Hepatol 2006; 4: 167-72.
3. van Wijk MP, Benninga MA, Omari TI. Role of the multichannel intraluminal impedance technique in infants and children. J Pediatr Gastroenterol Nutr 2009; 48: 2-12.
4. Silny J. Intraluminal Multiple Electric Impedance Procedure for Measurement of Gastrointestinal Motility. J Gastrointest Mot 1991; 3: 151-62.
5. Loots CM, van Wijk MP, Smits MJ et al. Measurement of Mucosal Conductivity by MII Is a Potential Marker of Mucosal Integrity Restored in Infants on Acid-suppression Therapy. J Pediatr Gastroenterol Nutr 2011; 53: 120-3.
6. Wasko-Czopnik D, Blonski W, Paradowski L. Diagnostic difficulties during combined multichannel intraluminal impedance and pH monitoring in patients with esophagitis or Barrett's esophagus. Adv Med Sci 2007; 52: 196-8.
7. Kessing BF, Bredenoord AJ, Weijenborg PW et al. Esophageal acid exposure decreases intraluminal baseline impedance levels. Am J Gastroenterol 2011; 106: 2093-7.
8. Farre R, Blondeau K, Clement D et al. Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique. Gut 2011; 60: 885-92.
9. Blonski W, Hila A, Vela MF et al. An analysis of distal esophageal impedance in individuals with and without esophageal motility abnormalities. J Clin Gastroenterol 2008; 42: 776-81.
10. Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005; 128: 771-8.
11. Farre R, Fornari F, Blondeau K et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. Gut 2010; 59: 164-9.
12. Chiba N, De Gara CJ, Wilkinson JM et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
13. Khan M, Santana J, Donnellan C et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; 2: CD003244.
14. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res 2009; 59: 135-53.
15. Moore DJ, Tao BS, Lines DR et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003; 143: 219-23.
16. Tighe MP, Afzal NA, Bevan A et al. Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review. Paediatr Drugs 2009; 11: 185-202.
17. Tolia V, Bishop PR, Tsou VM et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40mg pantoprazole in children (5-11years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2006; 42: 384-91.
18. Tolia V, Youssef NN, Gilger MA et al. Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatr 2010; 10: 41.
19. Higginbotham TW. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease. Ann Pharmacother 2010; 44: 572-6.
20. van der Pol RJ, Smits MJ, van Wijk MP et al. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics 2011; 127: 925-35.
21. Chen IL, Gao WY, Johnson AP et al. Proton Pump Inhibitor Use in Infants: FDA Reviewer Experience. J Pediatr Gastroenterol Nutr 2012; 54: 8-14.
22. Vandenplas Y, Rudolph CD, Di Lorenzo C et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009; 49: 498-547.
23. Orenstein SR. Symptoms and reflux in infants: infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R)--utility for symptom tracking and diagnosis. Curr Gastroenterol Rep 2010; 12: 431-6.
24. Farre R, De Vos R, Geboes K et al. Critical role of stress in increased oesophageal mucosa permeability and dilated intercellular spaces. Gut 2007; 56: 1191-7.
25. Farre R, van Malenstein H, De Vos R et al. Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces. Gut 2008; 57: 1366-74.
26. Tobey NA, Carson JL, Alkiek RA et al. Dilated intercellular spaces: a morphological feature of acid reflux--damaged human esophageal epithelium. Gastroenterology 1996; 111: 1200-5.
27. Tobey NA, Hosseini SS, Argote CM et al. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am J Gastroenterol 2004; 99: 13-22.
28. Carlsson R, Fandriks L, Jonsson C et al. Is the esophageal squamous epithelial barrier function impaired in patients with gastroesophageal reflux disease? Scand J Gastroenterol 1999; 34: 454-8.